Macrocyclic Nucleoside Phosphoramidate Derivatives for HCV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies for HCV are limited by high variability of the virus, persistence, drug-resistant mutants, and lack of effective small-animal models, leading to inadequate treatment options with significant side effects.
Innovation Solution
Development of macrocyclic nucleoside phosphoramidate derivatives represented by specific chemical formulas, which act as antiviral and antiproliferative agents, targeting the HCV NS5B polymerase to inhibit viral replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral therapies are used for HCV, then treatment is provided, but high variability of the virus and development of drug-resistant mutants reduce effectiveness
Solution Approach 1:
The patent modifies the chemical structure of nucleoside phosphoramidate derivatives by changing parameters such as the macrocyclic ring size (7-14 members), substituent groups (R1-R6, W, M), and stereochemistry to create compounds with enhanced antiviral activity and reduced susceptibility to viral resistance mechanisms
Solution Approach 2:
The invention creates composite molecular structures combining nucleoside analogs with phosphoramidate moieties within macrocyclic frameworks, integrating multiple functional elements (base, sugar, phosphate, and variable side chains) to achieve broad-spectrum antiviral activity against HCV
2Reliability
If existing antiviral drugs are administered, then viral replication is inhibited, but significant side effects occur
Solution Approach 1:
The patent introduces local modifications at specific positions in the nucleoside phosphoramidate structure (such as substituents at R2a, R2b, R3, R6 positions) to enhance selectivity for HCV NS5B polymerase while reducing off-target effects and toxicity to host cells
Solution Approach 2:
The invention develops prodrug formulations that are rapidly converted to active metabolites, providing sustained antiviral activity with reduced accumulation of toxic intermediates, effectively using temporary, easily metabolized molecular structures
3Reliability
If macrocyclic nucleoside phosphoramidate derivatives are developed, then antiviral efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent divides the macrocyclic nucleoside phosphoramidate structure into distinct functional segments (nucleoside base, sugar moiety, phosphoramidate linkage, and variable side chains) that can be independently optimized and synthesized through modular approaches
Solution Approach 2:
The invention incorporates flexible macrocyclic rings with variable sizes (7-14 members) and rotatable bonds that can adapt to different binding conformations in the HCV NS5B polymerase active site, providing structural flexibility without excessive rigidity
Data Source
AI summary
The present invention provides nucleoside phosphoramidate compounds of Formula I,where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.